Cytosorbents outlines cash flow breakeven path for second half of 2026 amid international sales growth

Earnings Call Insights: Cytosorbents Corporation (CTSO) Q4 2025

MANAGEMENT VIEW

* CEO Phillip Chan described 2025 as “a transitional year for the company, during which we made measurable progress across four key priorities,” including driving sales growth outside of Germany, advancing DrugSorb-ATR through the FDA process, and restructuring for long-term success in Germany. He highlighted that “full year 2025 sales revenues increased 4% to $37.1 million, representing record core product sales,” with direct sales outside Germany increasing 13% and distributor sales up 11.4%.
* CEO Chan reported a 10% decline in German sales to $11.8 million, attributed to restructuring, but noted “early signs of improvement in the first quarter of 2026” in Germany. He also detailed the launch of the PuriFi hemoperfusion pump and the HotSwap cartridge exchange system, with PuriFi aiming to “expand access in regions with limited dialysis infrastructure.”
* On DrugSorb-ATR, CEO Chan said, “we made important progress with the FDA. While our initial De Novo submission was denied, the appeal outcome provided two critical positives. One, there were no concerns regarding device safety; and two, there was alignment that a new submission can focus only on the remaining open items.”
* CFO Peter Mariani stated, “Full year 2025 revenue was $37.1 million, up 4% compared to a year ago and flat on a constant currency basis... Gross margin was 71% for the year compared to 70% for 2024.” He added, “operating loss for 2025 improved by 10% to $14.7 million compared to $16.5 million in 2024.”

OUTLOOK

* CEO Chan confirmed the company’s focus remains on “consistent revenue growth, executing the Germany turnaround, advancing DrugSorb-ATR towards FDA market authorization and achieving cash flow breakeven.”
* CFO Mariani indicated, “we expect operating cash burn to continue to decrease as these working capital dynamics normalize over the first half of the year and now expect to be operating cash flow breakeven in the second half of 2026.”
* Management maintained the goal of returning Germany to growth and leveraging innovations like PuriFi and HotSwap for future revenue expansion.

FINANCIAL RESULTS

* CFO Mariani reported, “For Q4 '25, revenue was $9.2 million, an increase of 1% year-over-year and down 8% on a constant currency basis compared to a year ago. Gross margin for Q4 '25 improved to 74%, up from 71% in Q4 of '24.”
* Operating expenses were $11.4 million for the quarter, including a $500,000 restructuring charge. Operating loss in Q4 was $4.6 million, and net loss improved to $5.5 million for the quarter or $0.09 per share compared to a net loss of $7.6 million or $0.14 per share in the prior year.
* Adjusted net loss for the quarter was $4.3 million or $0.07 per share. Cash, cash equivalents and restricted cash totaled $7.8 million as of December 31.

Q&A

* Michael Sarcone, Jefferies: Asked about FDA regulatory timelines and consensus with the agency. CEO Chan responded, “we continue to be in interactive discussions with the FDA…when we have some better visibility on the completion of those discussions, we'll let our shareholders know.”
* Sarcone followed up on confidence regarding alignment with the FDA. CEO Chan stated, “we believe that, that is still the regulatory path that we're going to be pursuing, but there are additional details…that we are working to define with FDA.”
* Sarcone inquired about progress in Germany. CEO Chan explained, “kind of a leadership change overall in the organization and a realignment of folks under that new reporting structure…very encouraged by…the team has really pitched in here.”
* Thomas Kerr, Zacks: Queried if the German restructuring is in the “later innings.” CEO Chan affirmed, “we believe we are…that plan is in place, and it's now about executing on that, and that's what we're focused on doing right now.”
* Kerr asked if gross margin can improve from 74%. CFO Mariani said, “we'll be happy keeping it in the…71%, 72%, 74% here consistently. That's what we're looking for.”
* Kerr questioned the PuriFi pump’s revenue model. CEO Chan compared it to the “printer cartridge business…we expect that to drive unit volume increases in our disposables like CytoSorb going forward. So it's an investment strategy…with hopefully a much larger payout in the future.”
* Xun Lee, H.C. Wainwright: Asked about achieving breakeven. CFO Mariani detailed, “we put the head count reductions in place in Q4…we're seeing reductions in those spend…we're on a good path to get there.”
* Lee also asked about de-risking the DrugSorb-ATR resubmission. CEO Chan said, “we've been very cautious and conservative to make sure that we are well aligned with FDA that there are no surprises.”

SENTIMENT ANALYSIS

* Analysts’ tone was neutral, with questions focused on regulatory timelines, Germany’s restructuring, and cost management. There was persistent interest in execution milestones and financial discipline.
* Management maintained a cautiously optimistic tone, emphasizing progress while acknowledging ongoing challenges. Phrases such as “we believe…” and “we are encouraged…” indicated careful optimism but not overconfidence.
* Compared to the previous quarter, both analysts and management maintained a pragmatic and methodical sentiment. The tone remained consistent, with no significant shift in confidence levels, though management provided more concrete updates on Germany and breakeven targets.

QUARTER-OVER-QUARTER COMPARISON

* Guidance language shifted from targeting cash flow breakeven in Q1 2026 to the second half of 2026, reflecting a more measured outlook on operational improvements.
* Strategic focus expanded with the launch of the PuriFi pump and HotSwap system, while the German market turnaround remained central.
* Analysts continued to focus on regulatory progress, gross margins, and restructuring execution.
* Key metrics reflected modest revenue growth and improved gross margins, but also highlighted persistent losses and ongoing restructuring costs.
* Management’s confidence in the restructuring process and product pipeline remained steady, with more explicit discussion of progress in Germany and FDA engagement.

RISKS AND CONCERNS

* Management cited continued execution challenges in Germany and the need to “align our cost structure to support a path to cash flow breakeven.”
* Regulatory uncertainty around DrugSorb-ATR persists, with CEO Chan noting ongoing discussions with the FDA and the need to avoid “another denial.”
* Analysts showed concern about the pace of operational improvements and the timeline for achieving breakeven.

FINAL TAKEAWAY

Cytosorbents’ management reiterated a focus on returning Germany to growth, advancing DrugSorb-ATR’s regulatory approval, and achieving cash flow breakeven in the second half of 2026. The company reported record product sales, incremental improvements from new product launches, and continued cost controls, while acknowledging ongoing challenges in Germany and the U.S. regulatory process. Management positioned these strategic initiatives as key to creating long-term value.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/ctso/earnings/transcripts]

MORE ON CYTOSORBENTS

* Cytosorbents Corporation (CTSO) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4885932-cytosorbents-corporation-ctso-q4-2025-earnings-call-transcript]
* Cytosorbents Non-GAAP EPS of -$0.07, revenue of $9.22M beats by $0.01M [https://seekingalpha.com/news/4568917-cytosorbents-non-gaap-eps-of-0_07-revenue-of-9_22m-beats-by-0_01m]
* Seeking Alpha’s Quant Rating on Cytosorbents [https://seekingalpha.com/symbol/CTSO/ratings/quant-ratings]
* Historical earnings data for Cytosorbents [https://seekingalpha.com/symbol/CTSO/earnings]
* Financial information for Cytosorbents [https://seekingalpha.com/symbol/CTSO/income-statement]